Inturlekin L33 in Ankylosing Spondylities Patients and Its Relation to Subclinical Atherosclerosis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: carotid duplex.
- Who it may be relevant to
- Registry conditions: Ankylosing Spondylitis. Basic parameters: 20 years — 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Inturlekin 33 in Ankylosing Spondylitis Patients and Its Relationship to Subclinical Atherosclerosis
Overview
detect level of Inturlekin 33 in ankylosing spondyilits patient measure CIMT (carotid intima media thickness ) by carotid duplex to detect subclinical atherosclerosis in ankylosing spondyitis patients detect the relation between IL33 and subclinical atherosclerosis in Ankylosinig Spondylitis patients
Detailed description
Ankylosing spondylitis (AS), a type of SpA, is an autoimmune disease that mainly involves, sacroiliac joints (SIJs) and their adjacent soft tissues, such as tendons and ligaments. The main clinical manifestations include back pain and progressive spinal rigidity as well as inflammation of the hips, shoulders, peripheral joints and fingers/toes. In addition, there are extra-articular manifestations.
Cardiovascular disease has become the first cause of death for patients with ankylosing spondylitis (AS).
Patients with ankylosing spondylitis (AS) have an increased cardiovascular morbidity and mortality . Accelerated atherosclerosis caused by a systemic inflammatory response has been reported to be an important risk factor for increased cardiovascular risk for autoimmune diseases.
Interleukin (IL)-33 is a cytokine belonging to the IL-1 family and was recently identified as a ligand for ST2, .the serum levels of IL-33/sST2 were remarkably higher in the patients with AS than the healthy groups .
Pervious studies confirm the importance of IL-33/ST2 axis in the process of atherosclerosis, and indicate its ambiguous function in immune response, whether as proinflammatory cytokine in advanced atherosclerotic lesions, or as profibrotic, in early lesions.
Previous study shows increased CIMT in AS patients without traditional cardiovascular risk factors compared to healthy controls.
Interventions
- Device carotid duplex
measure Carotid intima media thickness
Primary outcome measures
- detect level of IL33 in AS patients [Time frame: 3 years]
Secondary outcome measures (1)
- detect the reation between IL33 and subclinical atherosclerosis in AS patients [Time frame: 3 years]
Eligibility criteria
Inclusion criteria
- patient diagnosed as Ankylosing Spondylitis
- Age (20-40)
Exclusion criteria
- Patients with other rheumatic diseases/other SPA types
- Participants with history of CVD event in past or present
- Patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months.
- Patient with other risk factor for atherosclerosis.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Center list to be confirmed — check the primary protocol.
Publications
- Li GX, Wang S, Duan ZH, Zeng Z, Pan FM. Serum levels of IL-33 and its receptor ST2 are elevated in patients with ankylosing spondylitis. Scand J Rheumatol. 2013;42(3):226-31. doi: 10.3109/03009742.2012.735700. Epub 2013 Feb 15. PMID 23409750
Identifiers
NCT: NCT06564155 · IL33 in Ankylosing spondylites